Note 5 – Settlement and Release Agreement - Theralink

During the year ended December 31, 2024, the Company entered into several financing transactions with Theralink Technologies, Inc. (“Theralink”) that culminated in an acquisition of Theralink assets. Pursuant to the Settlement and Release Agreement dated May 1, 2024, the Company acquired certain assets which resulted in the recording of long lived assets of $1.1 million. The receivables of $1.1 million under the senior secured convertible debentures of Theralink (the “Theralink Notes”) was settled as part of the arrangement. In addition, in order to receive releases from security holders of Theralink, the Company issued 24,172 shares of Series E preferred stock. The Series E preferred stock was valued at a de minimis value. Series E preferred stock does not have any voting rights and each preferred share has a conversion price of $3.641 per share.